AO-176 Clinical Programs

AO-176 is a highly differentiated, best-in-class anti-CD47 antibody with the potential to improve upon the safety and efficacy profile of other agents in this class of checkpoint inhibitors.  AO-176 works by blocking the “don’t eat me” signal for macrophages, the standard mechanism of anti-CD47 antibodies. However, beyond blocking this signal, AO-176 has additional mechanisms including both directly killing tumor cells and inducing DAMPs (Damage Associated Molecular Patterns) resulting in Immunogenic Cell Death. Importantly, AO-176 binds preferentially to CD47 on tumor cells, instead of normal cells, and binds even more potently in low pH conditions such as the tumor microenvironment.

AO-176 is being evaluated in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies. In a Phase 1 trial in solid tumors, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity when administered as a single agent. Additional information about these trials may be found at using the trial identification number NCT03834948 (solid tumors) or NCT04445701 (multiple myeloma).

Our next-generation anti-CD47 antibody AO-176 is highly differentiated with a best-in-class profile